BIOCRYST PHARMACEUTICALS INC
BIOCRYST PHARMACEUTICALS INC (BCRX): 42 pipeline candidates · 12 upcoming catalysts · ~13 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
13.4 months
D/E -1.84 · 0% dilution
Lead: Approved
42 candidates
12 upcoming, next in ~3d
0 buys · 5 sells (180d)
A transparent, data-derived signal for BIOCRYST PHARMACEUTICALS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.2B
Cash
$173.4M
Quarterly Burn
$61.8M
Runway
13.4 mo
Revenue
$156.4M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (42 candidates)
| Drug | Phase |
|---|---|
| Adavosertib | Phase 2 |
| Afatinib | Phase 2 |
| Afatinib Dimaleate | Phase 2 |
| Avoralstat | Phase 1 |
| BCX10013 | — |
| BCX17725 | Phase 1 |
| Berotralstat | Phase 3 |
| Binimetinib | Phase 2 |
| Capivasertib | Phase 2 |
| company's new | Approved |
Showing 10 of 42 candidates. Sign up for full pipeline.
Upcoming Catalysts (12)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
299
Total value held
$2.44B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 22,650,988 | $215.6M |
| vanguard capital management llc | 22,271,524 | $212.0M |
| janus henderson group plc | 17,817,012 | $169.7M |
| ra capital management, l.p. | 15,827,186 | $150.7M |
| deerfield management company, l.p. | 15,038,000 | $143.2M |
| perceptive advisors llc | 14,868,066 | $141.5M |
| state street corp | 12,208,360 | $116.2M |
| vanguard portfolio management llc | 11,244,625 | $107.0M |
| two sigma investments, lp | 6,392,628 | $60.9M |
| geode capital management, llc | 5,782,776 | $55.1M |
Showing top 10 of 299 institutional holders of BIOCRYST PHARMACEUTICALS INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in BIOCRYST PHARMACEUTICALS INC's pipeline?
BIOCRYST PHARMACEUTICALS INC (BCRX) has 42 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is BIOCRYST PHARMACEUTICALS INC's lead drug candidate?
BIOCRYST PHARMACEUTICALS INC's most advanced tracked candidate is Adavosertib (Phase 2) for Advanced Lymphoma.
What is BIOCRYST PHARMACEUTICALS INC's next catalyst?
BIOCRYST PHARMACEUTICALS INC's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: SPRYCEL" — expected June 21, 2026.
What is BIOCRYST PHARMACEUTICALS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, BIOCRYST PHARMACEUTICALS INC has approximately 13.4 months of cash runway.
What is BIOCRYST PHARMACEUTICALS INC's market capitalization?
BIOCRYST PHARMACEUTICALS INC's market capitalization is approximately $2.2B.
Get the full picture on BIOCRYST PHARMACEUTICALS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.